Stockscreener 앱 받기
1.11
0.00%
0.00
시간 외 거래:
1.12
0.01
+0.90%
전일 마감가:
$1.11
열려 있는:
$1.11
하루 거래량:
536.97K
Relative Volume:
0.97
시가총액:
$94.95M
수익:
-
순이익/손실:
$-49.87M
주가수익비율:
-0.5652
EPS:
-1.964
순현금흐름:
$-19.36M
1주 성능:
+7.77%
1개월 성능:
-12.94%
6개월 성능:
-29.30%
1년 성능:
-42.78%
1일 변동 폭
$1.08
$1.17
1주일 범위
$1.0101
$1.17
52주 변동 폭
$0.9502
$2.18
Rein Therapeutics Inc Stock (RNTX) Company Profile
명칭
Rein Therapeutics Inc
전화
(737) 802-1989
주소
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.11 | 94.95M | 0 | -49.87M | -19.36M | -1.964 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-22 | 개시 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2017-07-24 | 개시 | BofA/Merrill | Buy |
| 2017-07-24 | 개시 | Jefferies | Buy |
| 2017-07-24 | 개시 | William Blair | Outperform |
Rein Therapeutics Inc 주식(RNTX)의 최신 뉴스
Rein Therapeutics director buys $49,560 in company stock By Investing.com - Investing.com Australia
Rein Therapeutics director buys $49,560 in company stock - Investing.com
Rein Therapeutics (RNTX) asks shareholders to double authorized shares to 200M - Stock Titan
RNTX Q1 2026 Earnings: EPS Beats Estimates as Preclinical Stage Biotech Tightens SpendingAnalyst Consensus Shift - Newser
RNTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Rein Therapeutics Advances PipelineProfit Growth Outlook - Newser
Rein Therapeutics (RNTX) Surges 7% as Stock Tests Key Resistance at $1.09Community Risk Signals - newser.com
Rein Therapeutics (RNTX) Q1 2026 Earnings Surprise: EPS $-0.19, Up SignificantHigh Estimate Range - Newser
Rein Therapeutics closes $57.5 million stock offering By Investing.com - Investing.com Nigeria
Rein Therapeutics announces closing of $57.5 million underwritten public offering - marketscreener.com
Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering - TradingView
Rein Therapeutics closes $57.5 million stock offering - Investing.com
Biotech Rein Therapeutics raises $57.5M for lung fibrosis trial - Stock Titan
Rein Therapeutics, Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics, Inc. 1Q 2026: Revenue $0 Net loss $(5.84)M, EPS $(0.19) — 10-Q Summary - TradingView
Rein Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
RNTX Technical Analysis | Trend, Signals & Chart Patterns | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill
Rein Therapeutics CEO Windsor buys $25,000 in common stock By Investing.com - Investing.com Nigeria
Rein Therapeutics CEO Windsor buys $25,000 in common stock - Investing.com
Rein Therapeutics (RNTX) quarterly results lack key metrics as company navigates strategic positioning, investors await clarityMomentum Score - newser.com
Number of shareholders of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Rein Therapeutics, Inc. News — NASDAQ:RNTX - TradingView
Should you add Rein Therapeutics (RNTX) to your watchlist today? (Trend Strengthens) 2026-05-08Viral Trade Signals - newser.com
Bios/Cavu investors disclose ~9.99% stake in Rein Therapeutics (RNTX) via preferred conversions - Stock Titan
Lynwood group owns 4.75M Rein Therapeutics (RNTX) shares (6.1%) - Stock Titan
Funicular Funds holds 5.195M shares in Rein Therapeutics (RNTX) — 6.7% - Stock Titan
Rein Therapeutics(RNTX) Stock Options Chain | Quotes & News - Moomoo
L. Lytton reports 4.5M shares in Rein Therapeutics (NASDAQ: RNTX) - Stock Titan
Rein Therapeutics, Inc.Common Stock (Nasdaq:RNTX) Stock Quote - The Chronicle-Journal
Rein Therapeutics Prices $50 Million Public Equity Offering - TipRanks
Rein Therapeutics (NASDAQ: RNTX) raises $50M, funds IPF trial into 2028 - Stock Titan
Rein Therapeutics (NASDAQ: RNTX) to sell 50M shares, nets ~$46.1M - Stock Titan
Rein Therapeutics stock dips after pricing $50M share offering - MSN
RNTX Slides As Rein Therapeutics Stock Tests New Lows - timothysykes.com
RNTX Stock Dips As Traders Weigh Deep Losses And Cash Runway - StocksToTrade
Rein Therapeutics Prices $50 Million Common Stock Offering; Shares Down Pre-Bell - Moomoo
Rein Therapeutics | EFFECT: Others - Moomoo
RNTX Stock Slides As Traders Eye Heavy Losses - timothysykes.com
Rein Therapeutics prices $50 million public offering at $1 - Investing.com
Rein Therapeutics prices $50 million public offering at $1 By Investing.com - Investing.com South Africa
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Rein Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock - Quiver Quantitative
Rein Therapeutics Inc prices public offering of 50 million shares at $1.00 per share for $50 million - marketscreener.com
Rein's $50M stock sale backs Phase 2 lung fibrosis study - Stock Titan
Rein Therapeutics Inc Prices Public Offering Of 50 Million Shares At $1.00 Per Share For $50 Million - TradingView
Rein Therapeutics' 50M-Share Offering Prices at $1 a Share - Moomoo
RNTX (Rein Therapeutics) shares drop 12 percent after Q4 2025 EPS misses analyst estimates by a massive margin.Crowd Breakout Signals - Newser
Rein Therapeutics provides clinical trial update for Phase 2 ReNEW Study of LTI-03 in idiopathic pulmonary fibrosis - marketscreener.com
RNTX - Finviz
Rein Therapeutics Provides Clinical Trial Update For Phase 2 Renew Study Of Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis - ChartMill
Rein Therapeutics Inc (RNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.37%
1.35%
자본화:
|
볼륨(24시간):